ILMN Illumina
- Official Name: ILLUMINA, INC.
- Headquarters: 5200 Illumina Way, SAN DIEGO, CA, 92122 US
- CEO: Jacob Thaysen
- Website: illumina.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1R | Won by 1.429 | (1.223) - (2.652) | ||
| 2025-07-18 | 1 | Won by 1.974 | (2.202) - (4.176) | ||
| 2025-07-23 | 1R | Won by 2.859 | 2.344 - (0.515) | ||
| 2025-07-25 | 2 | Lost by 0.931 | 11.704 - 12.635 | ||
| 2025-07-29 | 2R | Lost by 0.556 | (1.433) - (0.877) | ||
| 2025-08-01 | 3 | Lost by 13.427 | (11.320) - 2.107 | ||
| 2025-08-06 | 2R | Lost by 3.302 | (2.389) - 0.913 | ||
| 2025-08-08 | 4 | Won by 0.040 | (0.300) - (0.340) | ||
| 2025-08-15 | 5 | Won by 6.032 | 6.104 - 0.072 | ||
| 2025-08-22 | 6 | Lost by 0.372 | 2.893 - 3.265 | ||
| 2025-08-29 | 7 | Lost by 5.120 | (1.979) - 3.141 | ||
| 2025-09-05 | 8 | Won by 2.337 | (1.094) - (3.431) | ||
| 2025-09-12 | 9 | Lost by 1.580 | (4.619) - (3.039) | ||
| 2025-09-19 | 10 | Won by 8.998 | 7.943 - (1.055) | ||
| 2025-09-26 | 11 | Lost by 12.797 | (9.927) - 2.870 | ||
| 2025-10-03 | 12 | Won by 9.454 TOTW | 10.656 - 1.202 | ||
| 2025-10-10 | 13 | Won by 0.314 | (7.931) - (8.245) | ||
| 2025-10-17 | 14 | Won by 0.831 | 1.550 - 0.719 | ||
| 2025-10-24 | 15 | Lost by 6.359 | 4.923 - 11.282 |
Latest News

Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat...

Immuno-Oncology Diagnostics Market to Reach $11.1B by 2030 as Checkpoint Inhibitor and Cell Therapy Pipelines Drive Demand for Companion Tests
Report Tracks Roche Diagnostics, Thermo Fisher, Illumina, Agilent and Guardant Health Among 132 Companies, With Forecasts by Assay Type, Technology, C...

Global Proteomic Biomarker Analytics Market: Five-Year Forecast by Application, Technology, Product, and End User | Double-Digit Growth Boosts Cancer Diagnostics and Drug Discovery
New 307-page intelligence report maps surging demand for targeted omics technologies, profiling strategic moves by Danaher, Roche, and Thermo Fisher S...

GTT Group Founder Michael Lubitz Joining Expert Panel at IAM Patent Transactions 2026 in San Diego
Global Technology Transfer Group, Inc. (GTT Group), a market leader and pioneer in patent analysis, patent transactions, and patent enterprise value s...

Iambic, an AI drug discovery specialist, banks $150M in an IPO
Part of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to...

$100 Invested In Illumina 15 Years Ago Would Be Worth This Much Today
Illumina (NASDAQ:ILMN) has outperformed the market over the past 15 years by 3.81% on an annualized basis producing an average annual return of 16.89%...

Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
Illumina, Inc. (NASDAQ: ILMN) today debuted the Illumina BioInsight Platform, the company's first unified software environment designed to help r...

Is Illumina (ILMN) Fully Valued Following Its Recall And AI Push?
Illumina recall and security risk in focus Illumina (ILMN) has drawn fresh attention after initiating a voluntary Class II recall of certain NovaSeq 6...

Did Illumina’s (ILMN) New SpliceAI2 Genomic Model Just Reframe Its Clinical Genomics Narrative?
In October 2026, Illumina announced SpliceAI2, a new genomic AI model that helps researchers better identify disease-relevant splice variants across r...

Illumina (ILMN) Starts Global Recall Of Diagnostic Sequencers Over Security Vulnerability
Illumina (NasdaqGS:ILMN) has begun a global voluntary recall of certain NovaSeq 6000Dx and NextSeq 550Dx diagnostic sequencers due to a server securit...

Illumina (ILMN) Stock May Be About Fair Value After Genomics AI Launch
Illumina has delivered a striking share price run over the past year, and that kind of move naturally raises a question about whether the current valu...

Illumina Earnings Preview: What to Expect
Illumina will release its third-quarter earnings later this month, and analysts anticipate a low single-digit bottom-line growth.
TD Cowen Maintains Hold on Illumina, Raises Price Target to $270
TD Cowen analyst Dan Brennan maintains Illumina (NASDAQ:ILMN) with a Hold and raises the price target from $210 to $270.

Mammogen Appoints Diagnostics Industry Leader, Dr. Robert S. Epstein, to Board of Directors
Accomplished diagnostics and precision medicine leader brings decades of experience shaping the scientific, commercial and market success of category-...

ValuEngine Weekly Commentary With Strategy Notes
U.S. equity markets were mixed this week, with broader gains across value, defensive, and cyclical sectors offset by weakness in technology and the NA...

Global Chromosomal Microarray Reflex Testing Market Report 2026-2030 | Capitalize on 9.1% CAGR as Thermo Fisher, LabCorp, Illumina, Agilent, and Natera Scale Precision Genomics
Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- "Chromosomal Microarray Reflex Testing Global Market Report 2026" has been added to ResearchAndMar...

Illumina’s (ILMN) Sequencing Business Is Recovering, But Is the Stock Getting Ahead of Itself?
Illumina, Inc. (NASDAQ:ILMN) has returned 118% over the past six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% ...

3 Profitable Stocks We Steer Clear Of
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition ...